You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

lenvatinib

Showing 1 - 25 of 454
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Liver Cancer, Hepatocellular Carcinoma, Resistant Cancer Trial in Shanghai (Lenvatinib Oral Product Plus VIC1911)

Not yet recruiting
  • Liver Cancer
  • +2 more
  • Lenvatinib Oral Product Plus VIC1911
  • Shanghai, China
    Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine,
Jan 30, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 30, 2023

GBM Trial (Lenvatinib, Pembrolizumab, Tumor Treating Fields (TTFields))

Not yet recruiting
  • GBM
  • Lenvatinib
  • +2 more
  • (no location specified)
Aug 2, 2023

Hepatocellular Carcinoma Trial in Seoul (Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib
  • Seoul, Korea, Republic of
    Asan Medical Center
Nov 14, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC)

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Jul 12, 2023

Solid Tumor, Adult Trial in Shanghai (Tislelizumab, Lenvatinib, Cryoablation)

Recruiting
  • Solid Tumor, Adult
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 13, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, sintilimab plus SIRT)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib, sintilimab plus SIRT
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Aug 8, 2023

Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Lenvatinib plus sintilimab, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Lenvatinib plus sintilimab
  • Lenvatinib
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Nov 2, 2022

Potentially Resectable Hepatocellular Carcinoma Trial (FOLFOX-HAIC+Lenvatinib+Envolizumab)

Not yet recruiting
  • Potentially Resectable Hepatocellular Carcinoma
  • (no location specified)
Nov 16, 2023

Hepatocellular Carcinoma Trial in Beijing (Lenvatinib Plus Tislelizumab, Transarterial Chemoembolization(TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib Plus Tislelizumab
  • Transarterial Chemoembolization(TACE)
  • Beijing, Beijing, China
    Nan Zhang
Apr 22, 2023

Hepatocellular Carcinoma Non-resectable Trial in Guangzhou (Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib)

Recruiting
  • Hepatocellular Carcinoma Non-resectable
  • Lenvatinib Plus I-125 Seed Brachytherapy
  • Lenvatinib
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Nov 2, 2022

Hepatocellular Carcinoma Trial (Cryoablation, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Cryoablation
  • +2 more
  • (no location specified)
May 31, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guanzhou (bTAE-HAIC, Lenvatinib, Camrelizumab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guanzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 24, 2023

PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,

Not yet recruiting
  • PD-1 Refractory Advanced Melanoma
  • Responder-Derived Fecal microbiota transplantation (R-FMT
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 1, 2023

Endometrial Cancer, Endometrial Adenocarcinoma Trial in Guangzhou (Cadonilimab, Lenvatinib)

Not yet recruiting
  • Endometrial Cancer
  • Endometrial Adenocarcinoma
  • Guangzhou, China
    Sun Yat-sen University Cancer Cetntre
Apr 9, 2023

Advanced Biliary Tract Cancer Trial (H101, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Advanced Biliary Tract Cancer
  • (no location specified)
Apr 11, 2023

Hepatocellular Carcinoma Trial (TACE(transcatheter arterial chemoembolization), lenvatinib, Icaritin soft capsules)

Not yet recruiting
  • Hepatocellular Carcinoma
  • TACE（transcatheter arterial chemoembolization）
  • +2 more
  • (no location specified)
Jun 5, 2023

Breast Tumors Trial in Hangzhou (Sindilimab, Nab-paclitaxel, Lenvatinib)

Not yet recruiting
  • Breast Neoplasms
  • Hangzhou, Zhejiang, China
    ZhejiangCH
Nov 17, 2023

Resectable Hepatocellular Carcinoma Trial (Tislelizumab, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Resectable Hepatocellular Carcinoma
  • (no location specified)
Mar 29, 2023

Unresectable Hepatocellular Carcinoma Trial in Nanchang (D-TACE, HAIC, Lenvatinib)

Recruiting
  • Unresectable Hepatocellular Carcinoma
  • Nanchang, Jiangxi, China
    The Second Affiliated Hospital of Nanchang University
Oct 14, 2022

Advanced Hepatocellular Carcinoma Trial in Chengdu (Lenvatinib combined with TACE and Camrelizumab)

Recruiting
  • Advanced Hepatocellular Carcinoma
  • Lenvatinib combined with TACE and Camrelizumab
  • Chengdu, Sichuan, China
    HuaXi hospital
Feb 12, 2023

Gastric Cancer Metastatic to Liver Trial in Shanghai (Cryoablation, Tislelizumab, Lenvatinib)

Not yet recruiting
  • Gastric Cancer Metastatic to Liver
  • Cryoablation
  • +2 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jun 6, 2023

Cadonilimab, Clear Cell Renal Cell Carcinoma, Neoadjuvant Therapy Trial in Guangzhou (Cadonilimab Combined With Lenvatinib)

Recruiting
  • Cadonilimab
  • +2 more
  • Cadonilimab Combined With Lenvatinib
  • Guangzhou, Other (Non U.s.), China
    Sun Yat-sen University Cancer Center
Nov 16, 2023

Hepatocellular Carcinoma Trial in Wuhan (Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 17, 2023

Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Head Neck Cancer Trial in United States (Lenvatinib

Completed
  • Head and Neck Squamous Cell Carcinoma
  • +3 more
  • Basking Ridge, New Jersey
  • +6 more
Oct 13, 2022